0 0 0 0 0 0.020946726043213 0.020946726043213 0.020946726043213
Sign Up Today X
Thanks for submitting the form.
Stockreport

Phenylketonuria Market to Reach New Heights by 2034, Driven by Innovative Therapies and Rising Diagnosis Rates | DelveInsight

BioMarin Pharmaceutical Inc. (BMRN)  More Company Research Source: PR Newswire
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
With several potential therapies, including Sepiapterin (PTC Therapeutics), NGGT002 (NGGT), JNT-517 (Jnana Therapeutics), Pegvaliase (BioMarin), and others under investigation, the phenylketonuria treatment landscape is expected to undergo substantial transformation between 2025 and 2034.LAS VEGAS, Feb. 18, 2026 /PRNewswire/ -- Recently published Phenylketonuria Market Insights report includes a comprehensive understanding of current treatment practices, phenylketonuria emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Phenylketonuria Market SummaryThe total phenylketonuria treatment market size is expected to grow positively by 2034 in the leading markets.The United States accounts for the largest market size of phenylketonuria, in comparison to EU4 (Germany, Italy, France, and Spain), the UK, and [Read more]
IMPACT SNAPSHOT EVENT TIME: BMRN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
BMRN alerts
from News Quantified
BMRN
NEWS
BMRN
Earnings
BMRN
Analyst Actions
BMRN
SEC Filings
Stockreport

Phenylketonuria Market to Reach New Heights by 2034, Driven by Innovative Therapies and Rising Diagnosis Rates | DelveInsight

BioMarin Pharmaceutical Inc.  (BMRN) 
More Company Research Source: PR Newswire
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
With several potential therapies, including Sepiapterin (PTC Therapeutics), NGGT002 (NGGT), JNT-517 (Jnana Therapeutics), Pegvaliase (BioMarin), and others under investigation, the phenylketonuria treatment landscape is expected to undergo substantial transformation between 2025 and 2034.LAS VEGAS, Feb. 18, 2026 /PRNewswire/ -- Recently published Phenylketonuria Market Insights report includes a comprehensive understanding of current treatment practices, phenylketonuria emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Phenylketonuria Market SummaryThe total phenylketonuria treatment market size is expected to grow positively by 2034 in the leading markets.The United States accounts for the largest market size of phenylketonuria, in comparison to EU4 (Germany, Italy, France, and Spain), the UK, and [Read more]
IMPACT SNAPSHOT
EVENT TIME:
BMRN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS